Influenza Vaccine :: Baxter clinical trial for pandemic H5N1 influenza vaccine
Baxter International Inc. (NYSE: BAX) announced final Phase I/II data for its adjuvant-free investigational pandemic H5N1 influenza vaccine and plans to initiate a Phase III clinical trial of the candidate vaccine in Europe to confirm the study results.